UNIVERSITY OF ALABAMA HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $268.2M
- Transactions
- 26,370
- Companies
- 40
- Average per transaction
- $10,170
Who reported the payments
| Amgen | $34,636,147 |
| Bristol Myers Squibb | $19,789,281 |
| Pfizer | $14,867,086 |
| Genentech, Inc. | $14,740,541 |
| Janssen Research & Development, LLC | $13,592,103 |
| AbbVie | $10,308,868 |
| Merck | $7,973,069 |
| CSL Behring | $7,607,146 |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,150,740 |
| Incyte Corporation | $6,758,178 |
| Novartis | $6,688,063 |
| AstraZeneca | $5,434,972 |
| E.r. Squibb & Sons, L.L.C. | $5,405,943 |
| Gilead | $4,937,073 |
| Eli Lilly | $4,076,548 |
| Seagen Inc. | $3,816,744 |
| BD | $3,666,960 |
| Regeneron | $3,573,482 |
| Lundbeck LLC | $3,503,968 |
| Servier Bioinnovation | $3,450,953 |
| Kyowa Kirin, Inc. | $3,213,294 |
| Abbott | $3,031,651 |
| Genmab A/s | $2,997,623 |
| Modernatx, Inc. | $2,907,034 |
| Sanofi | $2,653,729 |
| Vertex | $2,413,122 |
| Biofire Diagnostics, LLC | $2,290,582 |
| Siemens Medical Solutions USA, Inc. | $2,180,056 |
| Biogen | $2,024,165 |
| Boston Scientific | $1,725,609 |
| Medtronic | $1,711,389 |
| Roche Molecular Systems, Inc. | $1,678,813 |
| Varian Medical Systems, Inc. | $1,447,257 |
| Boehringer Ingelheim | $1,420,610 |
| UCB SA | $1,274,510 |
| Roche TCRC, Inc. | $1,246,208 |
| Otsuka Pharmaceutical Co., Ltd. | $1,221,309 |
| Mayne Pharma Commercial LLC | $1,176,476 |
| Acadia Pharmaceuticals Inc | $1,172,761 |
| United Therapeutics Corporation | $1,011,968 |